Mohammad Atiq

498 total citations
21 papers, 155 citations indexed

About

Mohammad Atiq is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Mohammad Atiq has authored 21 papers receiving a total of 155 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 14 papers in Oncology and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Mohammad Atiq's work include Prostate Cancer Treatment and Research (13 papers), Cancer Immunotherapy and Biomarkers (11 papers) and Radiopharmaceutical Chemistry and Applications (3 papers). Mohammad Atiq is often cited by papers focused on Prostate Cancer Treatment and Research (13 papers), Cancer Immunotherapy and Biomarkers (11 papers) and Radiopharmaceutical Chemistry and Applications (3 papers). Mohammad Atiq collaborates with scholars based in United States, New Zealand and Japan. Mohammad Atiq's co-authors include Thomas Kieber‐Emmons, Issam Makhoul, Subhiksha Nandakumar, Gwo‐Shu Mary Lee, Yuki Yoshikawa, Philip W. Kantoff, Goutam Chakraborty, Ying Z. Mazzu, Joshua Armenia and Afshan Bhatti and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Mohammad Atiq

20 papers receiving 154 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mohammad Atiq United States 6 88 64 54 49 26 21 155
Avi Spira United States 3 121 1.4× 63 1.0× 72 1.3× 76 1.6× 59 2.3× 7 202
Mario Sznol United States 9 135 1.5× 45 0.7× 41 0.8× 96 2.0× 14 0.5× 21 187
Tokiyoshi Tanegashima Japan 6 98 1.1× 43 0.7× 46 0.9× 82 1.7× 26 1.0× 16 163
Jonathan Grivel France 7 114 1.3× 55 0.9× 45 0.8× 60 1.2× 22 0.8× 9 171
Georgia Spain United Kingdom 4 97 1.1× 25 0.4× 90 1.7× 69 1.4× 37 1.4× 6 164
Marco Moreira France 7 132 1.5× 105 1.6× 96 1.8× 50 1.0× 31 1.2× 10 208
Charlotte Aaquist Haslund Denmark 7 89 1.0× 30 0.5× 37 0.7× 35 0.7× 18 0.7× 29 149
Blanca Navarro Rodrigo Switzerland 3 115 1.3× 38 0.6× 33 0.6× 79 1.6× 17 0.7× 6 160
Xu-Shan Sun France 7 124 1.4× 80 1.3× 36 0.7× 31 0.6× 22 0.8× 13 193
Ahmed Bilal Khalid United States 3 145 1.6× 103 1.6× 70 1.3× 54 1.1× 29 1.1× 7 241

Countries citing papers authored by Mohammad Atiq

Since Specialization
Citations

This map shows the geographic impact of Mohammad Atiq's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mohammad Atiq with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mohammad Atiq more than expected).

Fields of papers citing papers by Mohammad Atiq

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mohammad Atiq. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mohammad Atiq. The network helps show where Mohammad Atiq may publish in the future.

Co-authorship network of co-authors of Mohammad Atiq

This figure shows the co-authorship network connecting the top 25 collaborators of Mohammad Atiq. A scholar is included among the top collaborators of Mohammad Atiq based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mohammad Atiq. Mohammad Atiq is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Atiq, Mohammad, et al.. (2023). Emerging treatment options for prostate cancer. Expert Review of Anticancer Therapy. 23(6). 625–631. 8 indexed citations
2.
3.
Atiq, Mohammad, Renee N. Donahue, Fatima Karzai, et al.. (2022). Evaluating the optimal sequence of immunotherapy and docetaxel in men with metastatic castration-sensitive prostate cancer.. Journal of Clinical Oncology. 40(6_suppl). 130–130. 3 indexed citations
4.
Atiq, Mohammad, Shruti U. Gandhy, Fatima Karzai, et al.. (2022). PSMA PET findings in patients with undetectable PSA more than 3 years after docetaxel for metastatic castration-sensitive prostate cancer (mCSPC).. Journal of Clinical Oncology. 40(16_suppl). e17046–e17046. 1 indexed citations
5.
Atiq, Mohammad, Fatima Karzai, Marijo Bilušić, et al.. (2022). Combining IL-12 immunocytokine (M9241) with docetaxel in metastatic prostate cancer: A phase I study.. Journal of Clinical Oncology. 40(16_suppl). e17033–e17033. 3 indexed citations
6.
Atiq, Mohammad, Shruti U. Gandhy, Fatima Karzai, et al.. (2021). Patients with undetectable PSA 2 years after docetaxel for metastatic castration sensitive prostate cancer (mCSPC).. Journal of Clinical Oncology. 39(15_suppl). e17044–e17044. 1 indexed citations
7.
Atiq, Mohammad, Marijo Bilušić, Fatima Karzai, et al.. (2021). A phase I/II study of bintrafusp alfa and NHS-IL12 in combination with docetaxel in adults with metastatic castration sensitive (mCSPC) and castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 39(15_suppl). TPS5096–TPS5096. 3 indexed citations
8.
Chakraborty, Goutam, Rahim Hirani, Subhiksha Nandakumar, et al.. (2020). Attenuation of SRC Kinase Activity Augments PARP Inhibitor–mediated Synthetic Lethality in BRCA2 -altered Prostate Tumors. Clinical Cancer Research. 27(6). 1792–1806. 17 indexed citations
9.
Mazzu, Ying Z., Joshua Armenia, Subhiksha Nandakumar, et al.. (2020). Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer. Molecular Oncology. 14(8). 1881–1897. 23 indexed citations
10.
Patel, Vijay, et al.. (2020). Pembrolizumab-Induced Cold Agglutinin Disease. American Journal of Case Reports. 21. e924283–e924283. 5 indexed citations
11.
Chakraborty, Goutam, Arnab Ghosh, Subhiksha Nandakumar, et al.. (2020). Fraction genome altered (FGA) to regulate both cell autonomous and non-cell autonomous functions in prostate cancer and its effect on prostate cancer aggressiveness.. Journal of Clinical Oncology. 38(6_suppl). 347–347. 7 indexed citations
12.
Chakraborty, Goutam, Mohammad Atiq, Subhiksha Nandakumar, et al.. (2019). Abstract 2534: A comparative analysis of fraction genome altered vs tumor mutational count in prostate cancer. Cancer Research. 79(13_Supplement). 2534–2534. 1 indexed citations
13.
Khan, Nabeela, Goutam Chakraborty, Subhiksha Nandakumar, et al.. (2019). Abstract 283: Combination treatment of PARP and SRC inhibitors in BRCA2 mutated prostate cancer. Cancer Research. 79(13_Supplement). 283–283. 1 indexed citations
14.
Atiq, Mohammad, et al.. (2018). A Unique Case of Severe Anemia Secondary to Copper Deficiency in an Adult Patient. Cureus. 10(11). e3636–e3636. 2 indexed citations
15.
Makhoul, Issam, et al.. (2018). Breast Cancer Immunotherapy: An Update. Breast Cancer Basic and Clinical Research. 12. 2220332306–2220332306. 57 indexed citations
16.
Chakraborty, Goutam, Joshua Armenia, Ying Z. Mazzu, et al.. (2018). BRCA2-RB1 co-loss and ADT resistance in aggressive prostate cancer.. Journal of Clinical Oncology. 36(15_suppl). e17024–e17024. 1 indexed citations
17.
Mazzu, Ying Z., Joshua Armenia, Goutam Chakraborty, et al.. (2018). Transcriptional and post-transcriptional regulation of ribonucleotide reductase (RRM2) control its oncogenic role in prostate cancer progression.. Journal of Clinical Oncology. 36(15_suppl). 5044–5044. 1 indexed citations
18.
Atiq, Mohammad, et al.. (2018). The Role of Immunotherapy and Radiation Therapy in Tumor Chemosensitivity in Advanced Head and Neck Cancer. American Journal of Case Reports. 19. 1241–1244. 4 indexed citations
19.
Atiq, Mohammad & Afshan Bhatti. (2014). The impact of incentives on Employees turnover at Pakistan InternationalContainer Terminal Limited (“PICT”) with respect to the different age brackets. IOSR Journal of Business and Management. 16(1). 53–60. 3 indexed citations
20.
Atiq, Mohammad, et al.. (2009). Ampullary metastasis from breast cancer: an unusual finding. Endoscopy. 41(S 02). E278–E279. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Avi Spira Breakdown of academic impact, for papers by Mario Sznol Breakdown of academic impact, for papers by Tokiyoshi Tanegashima Breakdown of academic impact, for papers by Jonathan Grivel Breakdown of academic impact, for papers by Georgia Spain Breakdown of academic impact, for papers by Marco Moreira Breakdown of academic impact, for papers by Charlotte Aaquist Haslund Breakdown of academic impact, for papers by Blanca Navarro Rodrigo Breakdown of academic impact, for papers by Xu-Shan Sun Breakdown of academic impact, for papers by Ahmed Bilal Khalid
Rankless by CCL
2026